Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

July 14, 2021
Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention Expects to Report Initial Clinical Data in Second Half of 2021  Sirnaomics, Inc., a biopharmaceutical... READ MORE
July 6, 2021
Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announces today... READ MORE
July 1, 2021
Sirnaomics Secures $105 Million Series E Financing Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic... READ MORE
June 30, 2021
Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer Company Expects to Report Interim Clinical Data of the Phase 2 in Second Half of... READ MORE
June 24, 2021
Sirnaomics Doses First Patient in Phase 1 Clinical Study of STP705 for Treatment of Liver Cancer Expects to Report Initial Clinical Data in Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2021 by Sirnaomics, Inc.
Contact